Vaxart, Inc.

    Jurisdiction
    United States
    ISIN
    US92243A2006 (VXRT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. Read full profile

    Fundamentals

    Net revenue
    €68.85M
    Gross margin
    100.0%
    EBIT
    -€47.34M
    EBIT margin
    -68.8%
    Net income
    -€48.31M
    Net margin
    -70.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €96.38M +40.0% -€90.58M +87.5%
    N/A -€192.51M +112.5%
    N/A -€197.80M +2.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $1.11
    Ex date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Finney Kevin N/A +167K $0.37 +$61.67K
    Watson W. Mark N/A +10K $0.41 +$4.10K

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 13, 2025 (Q2 2025)

    Add to watchlist

    Notifications